Portal versus peripheral circulating tumor cells as prognostic biomarkers in patients with stage I–III pancreatic ductal adenocarcinoma

Abstract

Background

The detection of portal venous circulating tumor cells (CTCs) may better reflect vascular metastasis and predict micrometastasis risk than peripheral blood in patients with pancreatic ductal adenocarcinoma (PDAC). We hypothesize that portal CTCs could better represent micrometastasis and can predict survival in PDAC patients.

Methods

A single-center, prospective cohort study of patients with stage I–III PDAC was conducted. Portal venous blood was obtained via endoscopic ultrasound-guided sampling, and peripheral blood was collected on the same day. CTCs were detected using EpCAM and mucin1 antibodies and reported as cells/8 mL of blood.

Results

Among 35 patients, the portal and peripheral CTC detection rates were 94.3% and 82.9%, respectively. Advanced PDAC with locoregional metastasis had higher portal CTCs than less aggressive disease (P < 0.05), while peripheral CTCs showed no significant differences. During the 50-month follow-up, patients with portal CTCs ≥8 had poorer survival (6.1 vs. 19.0 months; P = 0.001) and patients with peripheral CTCs ≥3 also had poorer survival (4.6 vs. 14.2 months; P = 0.002). In multivariable analysis, both portal CTCs ≥8 and peripheral CTCs ≥3 showed significant adjusted associations with survival (adjusted hazard ratio 3.4 [P = 0.009] and 2.7 [P = 0.02], respectively).

Conclusion

Higher CTC counts in both the portal and peripheral systems were significantly associated with poorer survival in stage I–III PDAC; however, only portal CTCs reflected tumor aggression and locoregional metastasis.

Publication History

Received: 26 August 2024

Accepted after revision: 07 February 2025

Accepted Manuscript online:
07 February 2025

Article published online:
27 March 2025

• References

• 1 Habli Z, AlChamaa W, Saab R. et al. Circulating tumor cell detection technologies and clinical utility: challenges and opportunities. Cancers (Basel) 2020; 12: 1930
• 2 Zhang ZH, Bao YW, Zhao YJ. et al. Circulating tumor cells as potential prognostic biomarkers for early-stage pancreatic cancer: A systematic review and meta-analysis. World J Clin Oncol 2023; 14: 504-517
• 3 Stephenson D, Nahm C, Chua T. et al. Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis. Oncotarget 2017; 8: 107223-107236
• 4 Huang L, Jansen L, Balavarca Y. et al. Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. BMC Med 2018; 16: 125
• 5 Ko SW, Yoon SB. Clinical implications and perspectives of portal venous circulating tumor cells in pancreatic cancer. World J Gastrointest Oncol 2023; 15: 632-643
• 6 Catenacci DV, Chapman CG, Xu P. et al. Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound. Gastroenterology 2015; 149: 1794-1803 e1794
• 7 Chapman CG, Ayoub F, Swei E. et al. Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers. Pancreatology 2020; 20: 1747-1754
• 8 Takao M, Takeda K. Enumeration, characterization, and collection of intact circulating tumor cells by cross contamination-free flow cytometry. Cytometry A 2011; 79: 107-117
• 9 Shmueli G. To explain or to predict?. Stat Sci 2010; 25: 289-310
• 10 Tien YW, Kuo HC, Ho BI. et al. A high circulating tumor cell count in portal vein predicts liver metastasis from periampullary or pancreatic cancer: a high portal venous CTC count predicts liver metastases. Medicine (Baltimore) 2016; 95: e3407
• 11 Liu X, Li C, Li J. et al. Detection of CTCs in portal vein was associated with intrahepatic metastases and prognosis in patients with advanced pancreatic cancer. J Cancer 2018; 9: 2038-2045
• 12 Zhang Y, Su H, Wang H. et al. Endoscopic ultrasound-guided acquisition of portal venous circulating tumor cells as a potential diagnostic and prognostic tool for pancreatic cancer. Cancer Manag Res 2021; 13: 7649-7661
• 13 Choi YH, Hong TH, Yoon SB. et al. Prognostic implications of portal venous circulating tumor cells in resectable pancreatic cancer. Biomedicines 2022; 10: 1289
• 14 Pang TCY, Po JW, Becker TM. et al. Circulating tumour cells in pancreatic cancer: A systematic review and meta-analysis of clinicopathological implications. Pancreatology 2021; 21: 103-114
• 15 Song BG, Kwon W, Kim H. et al. Detection of circulating tumor cells in resectable pancreatic ductal adenocarcinoma: a prospective evaluation as a prognostic marker. Front Oncol 2020; 10
• 16 Padillo-Ruiz J, Suarez G, Pereira S. et al. Circulating tumor cells enumeration from the portal vein for risk stratification in early pancreatic cancer patients. Cancers (Basel) 2021; 13: 6153
• 17 Chapman CG, Waxman I. EUS-guided portal vein sampling. Endosc Ultrasound 2018; 7: 240-245
• 18 White MG, Lee A, Vicente D. et al. Measurement of portal vein blood circulating tumor cells is safe and may correlate with outcomes in resected pancreatic ductal adenocarcinoma. Ann Surg Oncol 2021; 28: 4615-4622
• 19 Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol 2013; 177: 292-298
• 20 Boileve A, Cartry J, Goudarzi N. et al. Organoids for functional precision medicine in advanced pancreatic cancer. Gastroenterology 2024; 167: 961-976 e913